Assessment of peripheral biomarkers and their correlation with oxidative stress index in schizophrenia: an integrated strategy
DOI:
https://doi.org/10.53992/njns.v11i2.319Keywords:
Schizophrenia, Oxidative Stress, Oxidative Stress Index (OSI), Inflammatory Markers, Antioxidant Status, Paraoxonase-1 (PON1).Abstract
The innovative search for in vivo biomarkers in schizophrenia today offers a new perspective on improving diagnosis and understanding the disease process. Currently, effective diagnostic methods for schizophrenia are extremely limited, despite the fact that it is a multifactorial health problem affecting less than 0.4% of the world’s population. The challenges to mental health in Pakistan are compounded by an over-reliance on traditional diagnostic techniques that yield mostly unsatisfactory results. Diagnostic difficulties can arise as a consequence of factors such as irregular and varied patient history, overlapping and unstable elements, and the number of inexperienced professionals, and diagnosis is frequently inexact. The target of the recent investigation is to investigation to estimate the results of tangential biomarkers like oxidants, antioxidants, and inflammatory markers and their association to the oxidative stress index (OSI) in schizophrenia. Standard approach were employed to gauge reactive protein (CRP), inflammatory markers, serum lipid levels, leukocyte indices, (PON1) Paraoxonase 1, total oxidant/antioxidant status (TAS and TOS), and (OSI) oxidative stress index in two groups: The study cohort comprised 50 patients with schizophrenia (Sz) and 50 healthy controls, with data analyzed using appropriate statistical methods. Findings confirmed the role of oxidative stress in schizophrenia and suggested that OSI could be used as a marker which in conjunction with other parameters might yield more accurate diagnoses. In schizophrenia, inflammation and oxidative stress appear to work together, and while OSI represents a useful quantitative index for more valuable diagnosis, additional evaluation, particularly in larger prospective trials, is warranted.
References
Yasmin F, Jatoi HN, Abbasi MS, Asghar MS, Siddiqui SA, Nauman H, et al. Psychological distress, anxiety, family violence, suicidality, and wellbeing in Pakistan during the COVID-19 lockdown: A cross-sectional study. Front Psychol. 2022; 13:830935.
Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal. 2011; 15(7): 2011-2035.
Miller BJ, Gassama B, Sebastian D, Buckley P, Mellor A. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2013;73(10):993-999.
Miller BJ, Buckley PF. Is relapse in schizophrenia an immune-mediated effect? Focus. 2012;10(2):115-123.
Madireddy S, Madireddy S. Regulation of reactive oxygen species-mediated damage in the pathogenesis of schizophrenia. Brain Sci. 2020;10(10): 742.
Yegin N, Ay O, Aydin N, Yargici E, Eren E, Yilmaz N. Increased Oxidant Stress and Inflammation in Patients with Chronic Schizophrenia. Int J Clin Med. 2012;3(5):368-376.
Singh B, Chaudhuri TK. Role of C-reactive protein in schizophrenia: an overview. Psychiatry Res. 2014;216(2): 277-285.
Boyapati R, Chinthalapani S, Ramisetti A, Salavadhi SS, Ramachandran R. Association of pentraxin and high-sensitive C-reactive protein as inflammatory biomarkers in patients with chronic periodontitis and peripheral arterial disease. J Indian Soc Periodontol. 2018;22(2):112-115.
Ermakov EA, Melamud MM, Buneva VN, Ivanova SA. Immune system abnormalities in schizophrenia: an integrative view and translational perspectives. Front Psychiatry. 2022; 13:880568.
Hong W, Zhao M, Li H, Peng F, Wang F, Li N, et al. Higher plasma S100B concentrations in schizophrenia patients, and dependently associated with inflammatory markers. Sci Rep. 2016;6:27584.
Manu P, Correll CU, Wampers M, Mitchell AJ, Probst M, Vancampfort D, et al. Markers of inflammation in schizophrenia: association vs. causation. World Psychiatry. 2014; 13(2):189.
Oracz AJ, Zwierz M, Naumowicz M, Modzelewski S, Suprunowicz M, Waszkiewicz N. Linking Metabolic Disorders and Immune System Phenomena in Schizophrenia: The Role of Adipose Tissue and Inflammation. Biomedicines. 2025;13(9):2308.
Busse S, Busse M, Schiltz K, Bielau H, Gos T, Brisch R, et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations? Brain Behav Immun. 2012; 26(8):1273-1279.
Ptasczynski LE, Steinecker I, Sterzer P, Guggenmos M. The value of confidence: Confidence prediction errors drive value-based learning in the absence of external feedback. PLoS Comput Biol. 2022;18(10):e1010580.
Miller BJ, Gassama B, Sebastian D, Buckley P, Mellor A. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2013;73(10):993-999.
Miller BJ, Goldsmith DR. Towards an immunophenotype of schizophrenia: progress, potential mechanisms, and future directions. Neuropsycho-pharmacology. 2017;42(1):299-317.
Wasti AZ, Haider S, Rashid S, Fatima N, Ashiq A, Iqbal S. The Biochemical Profile of Chronic Kidney Disease Patients. RADS J Biol Res Appl Sci. 2013;4(1):05-10.
Joseph J, Depp C, Martin AS, Daly RE, Glorioso DK, Palmer BW, et al. Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups. Schizophr Res. 2015;168(1-2):456-460.
Zhao X, Zhu W, Bu Y, Li J, Hao Y, Bi Y. Effects of 6-week olanzapine treatment on serum IL-2, IL-4, IL-8, IL-10, and TNF-α levels in drug-naive individuals with first-episode schizophrenia. BMC Psychiatry. 2024; 24(1):703.
Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry. 2011;68(2):128-137.
Tran MT, Gomez SV, Alenicheva V, Remcho VT. A paper-based assay for the determination of total antioxidant capacity in human serum samples. Biosensors. 2024;14(11):559.
Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, et al. Oxidative stress: harms and benefits for human health. Oxid Med Cell Longev. 2017;2017:8416763.
Feng J, Zheng Y, Guo M, Ares I, Martinez M, Lopez-Torres B, et al. Oxidative stress, the blood–brain barrier and neurodegenerative diseases: The critical beneficial role of dietary antioxidants. Acta Pharm Sin B. 2023;13(10):3988-4024.
Perkovic MN, Erjavec GN, Strac DS, Uzun S, Kozumplik O, Pivac N. Theranostic biomarkers for schizophrenia. Int J Mol Sci. 2017; 18(4):733.
Deng ZH, Zhong J, Jiang HL, Jeong HW, Chen JW, Shu YH, et al. Antipsychotic drugs induce vascular defects in hematopoietic organs.
FASEB J. 2022;36(10):e22538.
Wasti AZ, Zahid S, Ahmed N. Antipsychotic Drugs Induced Iron Deficiency Anemia in Schizophrenic Patients. Int J Adv Res. 2013;1(10): 111-118.
Jackson AJ, Miller BJ. Meta-analysis of total and differential white blood cell counts in schizophrenia. Acta Psychiatr Scand. 2020;142(1):18-26.
Akbaş S, Turla A, Karabekiroğlu K, Pazvantoğlu O, Keskin T, Böke O. Characteristics of sexual abuse in a sample of Turkish children with and without mental retardation, referred for legal appraisal of the psychological repercussions. Sex Disabil. 2009; 27(4):205-213.
Copoglu US, Virit O, Kokacya MH, Orkmez M, Bulbul F, Erbagci AB, et al. Increased oxidative stress and oxidative DNA damage in non-remission schizophrenia patients. Psychiatry Res. 2015;229(1-2):200-205.
Yegin A, Ay N, Aydin O, Yargici N, Eren E, Yilmaz N. Increased oxidant stress and inflammation in patients with chronic schizophrenia. Int J Clin Med. 2012;3(5):368-376.
